Tumor Lysis Syndrome (TLS) Market Spotlight Report 2021 - ResearchAndMarkets.com

·2 min read

DUBLIN, January 27, 2022--(BUSINESS WIRE)--The "Market Spotlight: Tumor Lysis Syndrome (TLS)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The publisher estimates that in 2017, there were approximately 12,400 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt's lymphoma)

  • The number of incident cases is forecast to increase to 13,600 by 2026. The marketed drugs for TLS comprise the xanthine oxidase inhibitors Aloprim (allopurinol) and Uloric (febuxostat), and a recombinant urate-oxidase enzyme, Elitek (rasburicase). These therapies are administered via the intravenous and oral routes.

  • The overall likelihood of approval of a Phase I hematologic asset is 9.3%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TLS have been in the late phases of development, with 67% of trials in Phase III-IV, and 33% in Phase II.

  • The US leads in terms of the number of TLS clinical trials globally, while Italy and Spain lead the major European markets. Clinical trial activity in the TLS space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for TLS, with eight in total.

  • Sanofi has carried out the most clinical trials in the TLS space, with Menarini being the only other trial sponsor.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Prophylaxis and monitoring

  • Volume expansion

  • Medical therapies

  • Renal replacement therapy

EPIDEMIOLOGY

  • Incidence assumptions

MARKETED DRUGS

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/w2ea46

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005876/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting